Regeneron Pharma Q4 Results Top Estimates - Update

RTTNews | 622天前
Regeneron Pharma Q4 Results Top Estimates - Update

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.37 billion or $11.86 per share, compared to $1.45 billion or $12.56 per share in the year-ago quarter.

On average, 21 analysts polled by Thomson Reuters expected the company to report earnings of $10.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter edged up 1 percent to $3.43 billion from $3.41 billion in the same quarter last year. Excluding Ronapreve, revenue grew 14 percent. Analysts were looking for revenues of $3.29 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | 441天前
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | 475天前
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | 1203天前
Canadian Market Pares Early Gains; Materials Stocks Stay Firm

Canadian Market Pares Early Gains; Materials Stocks Stay Firm

After opening on a firm note and climbing further up north, the Canadian market pared gains and drifted down into negative territory on Thursday, weighed down by losses in energy, financials and industrials sectors.
RTTNews | 3小時42分鐘前
Swiss Market Ends On Strong Note

Swiss Market Ends On Strong Note

Swiss stocks closed on a strong note on Thursday, tracking positive cues from other markets across Europe, amid rising prospects of another rate cut by the Federal Reserve, and easing political tensions in France.
RTTNews | 4小時12分鐘前
U.S. Homebuilder Confidence Improves Much More Than Expected In October

U.S. Homebuilder Confidence Improves Much More Than Expected In October

A report released by the National Association of Home Builders on Thursday showed homebuilder confidence in the U.S. has improved by much more than anticipated in the month of October. The report said the NAHB/Wells Fargo Housing Market Index jumped to 37 in October after holding steady at 32 in September. Economists had expected the index to inch up to 33.
RTTNews | 7小時42分鐘前